Otorhinolaryngology Department Hospital Clinic, Barcelona, Spain.
Otorhinolaryngology Department Hospital Clinic, Barcelona, Spain.
Int J Pediatr Otorhinolaryngol. 2020 Oct;137:110194. doi: 10.1016/j.ijporl.2020.110194. Epub 2020 Jul 10.
Recurrent respiratory papillomatosis (RRP) is a chronic disease caused by human papillomavirus (HPV). RRP is a clinical challenge because of the high recurrence rate, poor surgery response, extension to tracheobronchial tree and because of the risk of malignancy in some cases. There is no consensus on which adjuvant therapy is better for those patients with highly recurrent course. Because papilloma cells overexpress the epidermal growth factor receptor (EGFR), together with an increased expression of COX-2 and prostaglandin E2, the combination of erlotinib and celecoxib seems plausible, and could be proposed for patients with poor response to previous lines of treatment.
复发性呼吸道乳头瘤病（RRP）是由人乳头瘤病毒（HPV）引起的慢性疾病。RRP 是一种临床挑战，因为其复发率高、手术反应差、向气管支气管树延伸以及在某些情况下存在恶性转化的风险。对于那些具有高复发病程的患者，哪种辅助治疗更好尚无共识。由于乳头瘤细胞过度表达表皮生长因子受体（EGFR），同时 COX-2 和前列腺素 E2 的表达增加，厄洛替尼和塞来昔布联合使用似乎是合理的，并可提议用于对先前治疗线反应不佳的患者。
